RxDoctor Payments Data

Janice Chang, MD

Dermatology · Webster, TXNPI 1659373579

Payments from drug & device makers

$3,074in general payments, 2019–2025

Across 132 payments — averaging $23.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$935
  • Sanofi$589
  • LEO Pharma Inc.$444
  • Johnson & Johnson$358
  • Novartis$170
  • Merz North America, Inc.$109
  • plus $469 from 10 others

What the payments were for

  • Speaking & faculty fees$2087%
  • Food & beverage$2,63386%
  • Education$2338%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,074 in reported general payments places this provider in the 40th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$388,844
Medicare patients
1,369
Services billed
6,523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab23$181,046
Humira(Cf) PenAdalimumab11$131,596
Enbrel SureclickEtanercept14$103,274
Dupixent PenDupilumab24$88,515
OtezlaApremilast12$61,682
Clobetasol Propionate155$6,579
Doxycycline Monohydrate269$6,243
Tacrolimus59$6,160
Pimecrolimus28$5,602
Ivermectin30$5,420
Fluorouracil83$5,032
Metronidazole99$4,740
Ketoconazole277$3,658
Azelaic Acid29$3,114
Fluocinonide71$2,715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$102$61,68212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,098 dermatology providers in Texas.

Other dermatology in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →